奥おく替がえ库单抗こう

奥おく替がえ库单抗こう
单克隆たかし抗体こうたい
种类	完かん整せい抗体こうたい
目標もくひょう	oxLDL
臨床りんしょう資料しりょう
其他名稱めいしょう	奥おく替がえ苏单抗こう、BI-204、MLDL1278A
ATC碼	未み分配ぶんぱい;
识别信しん息いき
CAS号ごう	1314241-10-5
ChemSpider	none;
UNII	2O892R8U24;

奥おく替がえ库单抗こう（INN：Orticumab；开发代だい号ごう：BI-204、MLDL1278A），或ある译奥おく替がえ苏单抗こう，是ぜ一いち种人单克隆たかし抗体こうたい，用作ようさく抗こう炎ほのお剂并与oxLDL结合。它充当じゅうとう免めん疫调节剂。^[1]该药物ぶつ可か以用来らい治ち疗动脉粥かゆ样硬化か。^[2]该药物ぶつ由ゆかりBioInvent公司こうし研究けんきゅう开发。^[3]

参考さんこう资料

^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-01-21]. （原始げんし内容ないよう存そん档 (PDF)于2016-03-04）.
^ Yao Mattisson, Ingrid; Rattik, Sara; Björkbacka, Harry; Ljungcrantz, Irena; Terrinoni, Manuela; Lebens, Michael; Holmgren, Jan; Fredrikson, Gunilla Nordin; Gullstrand, Birgitta; Bengtsson, Anders A.; Nilsson, Jan. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascular Pharmacology. 2021-10-01, 140 [2024-01-21]. ISSN 1537-1891. doi:10.1016/j.vph.2021.106863. （原始げんし内容ないよう存そん档于2024-07-16）.
^ Recruitment of patients completed in phase II study with BI-204. BioInvent. 2012-03-02 [2024-01-21] （英えい语）.

[1] World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-01-21]. （原始げんし内容ないよう存そん档 (PDF)于2016-03-04）.

[2] Yao Mattisson, Ingrid; Rattik, Sara; Björkbacka, Harry; Ljungcrantz, Irena; Terrinoni, Manuela; Lebens, Michael; Holmgren, Jan; Fredrikson, Gunilla Nordin; Gullstrand, Birgitta; Bengtsson, Anders A.; Nilsson, Jan. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascular Pharmacology. 2021-10-01, 140 [2024-01-21]. ISSN 1537-1891. doi:10.1016/j.vph.2021.106863. （原始げんし内容ないよう存そん档于2024-07-16）.

[3] Recruitment of patients completed in phase II study with BI-204. BioInvent. 2012-03-02 [2024-01-21] （英えい语）.

[1]

[2]

[3]